Interventional clinical trials in acute severe ulcerative colitis (ASUC) are characterized by substantial heterogeneity due to a lack of consensus in several key areas of trial design -- this impedes ...
p #60; 0.001. Data from [74]. Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA ...
Palisade Bio, Inc. announced positive preclinical results for its drug candidate PALI-2108 at the 2025 Crohn’s and Colitis Congress, showing its efficacy in reducing colitis symptoms in a DSS mouse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results